Research-integrity sleuths have identified roughly 203 images in Thermo Fisher Scientific's online antibody catalogue that share the same copied-and-pasted background pattern — part of a wider set of hundreds of validation Western blots that appear digitally altered, including instances where off-target binding bands look painted over or "scratched out."

The findings, discussed on Chemistry World's Chemical Breakdown podcast with digital content assistant Frankie Macpherson and business editor Phillip Broadwith, put one of the world's largest laboratory suppliers at the centre of a data-integrity dispute with direct consequences for lab budgets and experimental planning.

What was manipulated, and how bad is it

Western blots separate proteins by molecular weight and serve as the validation evidence that an antibody binds its intended target and nothing else. The altered catalogue images fall into two categories. The most serious cases show "apparent painting" — removal of bands indicating off-target binding, which would signal an antibody does not perform as advertised. In others, a clean background appears copied from one blot and reused across many products, with bands pasted on top.

Thermo Fisher maintains the changes were cosmetic, made for presentation clarity, and says it remains confident in reagent performance. Researchers who spoke with Macpherson disagreed on where the acceptable-cosmetics line sits, but all agreed some examples go well beyond it.

"The best case is the real data is there, but it's a bit messy. They've taken what is real data and just put it onto a cleaner background, which wouldn't be acceptable for publication in a journal," said Broadwith. "The worst case is they haven't done [the blot], and it's just copied and pasted. But that's absolutely not clear."

The core problem is verifiability. Journals set image-integrity standards for published work, but no agreed standard governs commercial validation data. Until Thermo Fisher releases original images — the company says researchers can request raw data and is running an internal review, but has not yet posted a central access page — buyers cannot distinguish tidied real data from hidden failures.

The cost falls on labs

Independent validation is not realistic for most groups. A 0.1 ml vial of antibody costs $400–500 (£300–400), and repeating blots consumes time and consumables on top. Researchers who spent months failing to get an antibody to work are now questioning whether the reagent or the experiment was at fault.

"The biggest thing is the uncertainty," said Broadwith. "We don't know whether your negative results are because the antibody is not working or because the experiment doesn't work."

Science-integrity analyst Elisabeth Bik, quoted by Macpherson, noted she trusts blots that show small impurities precisely because they look real — raising the question of whether catalogue-wide cleanup has artificially inflated expectations of how clean validation data should appear.

The story is expanding. Sleuths maintain a continuously updated repository and expect many more images to surface; one image from competitor Abcam shows a background pattern matching Thermo Fisher examples. Some affected blots came from Thermo Fisher's internal analysis, others from third-party suppliers. The independent validation organisation Icarus, which uses gold-standard protocols, is one candidate mechanism for restoring confidence. Broadwith's bottom line for vendors: customers, often spending public science funding, "absolutely need to be working hard to restore the trust of their customers."

Chemical recycling contracts under economic pressure

The second story examined in the episode: chemical recycling is shrinking across Europe and the US despite a decade of policy momentum on plastic waste.

The baseline numbers frame the challenge. Only about a third of European plastic waste is recycled at all, roughly 10% in the US, and chemical recycling accounts for perhaps 0.1% of total recycling — the rest is mechanical. Pyrolysis and related processes break carbon–carbon bonds to yield hydrocarbon mixtures, but they still require clean, consistent feedstock. Mixed or contaminated inputs — PVC's chlorine in particular — degrade output quality and push yield toward low-value products destined for burning.

Economics compound the technical limits. Virgin plastic prices have fallen as China, having built petrochemical capacity for self-sufficiency, no longer absorbs global supply. Recycled material, already more expensive because of collection and processing costs, faces rising energy prices that hit energy-intensive pyrolysis twice over. Even when Middle East conflict pushed virgin prices up, recyclers gained no advantage because their own costs rose in parallel.

Policy was supposed to bridge the gap. EU rules mandating minimum recycled content and virgin-plastic carbon taxes are coming, but repeated delays stretch developer timelines until, as Broadwith put it, "their money runs out." Some US plants closed not for cost reasons but because regulators judged their emissions and hazardous waste excessive — a counterintuitive failure mode for an environmental technology.

Design-for-recycling offers a parallel path: UK milk bottles switched caps to the bottle body's polymer to simplify recycling. But performance requirements, such as gas-barrier multilayers, limit how far mixing can be reduced, and changes percolate slowly.

On the international stage, Broadwith noted that most countries negotiating plastic-waste treaties favour cutting production overall, while a small number of petrochemical-dependent states block reduction targets. His own reading: both production cuts and better waste infrastructure are needed, and neither is politically easy.

Whether chemical recycling represents normal growing pains or over-promising remains unresolved — governments could still make it work with sufficient support, though whether that money is best spent elsewhere is, as Broadwith acknowledged, a separate question.